Orchard to build new gene therapy manufacturing facility

13 December 2018

UK and USA-based clinical-stage biotech Orchard Therapeutics (Nasdaq: ORTX) has signed a long-term lease agreement to build-out a gene therapy manufacturing facility in Fremont, California.

The company says that the new site will enhance Orchard’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for a wide range of diseases on a global scale.

Building of the new manufacturing facility is expected to begin in 2019, and Orchard expects to hire more than 100 full-time employees over the next few years to support in-house manufacturing efforts. The company already has two sites in California.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK